Abstract
Background: Muscle-strengthening activities have been recommended for health benefits. However, it is unclear whether resistance training is associated with cancer risk, independent of total physical activity. Methods: A prospective cohort study followed 33,787 men from the Health Professionals Follow-up Study (1992–2014). Cumulative average of resistance training (hours/week) was assessed through biennial questionnaires up to 2 years before cancer diagnosis. Cox regression model was used to estimate the hazard ratio (HR) and 95% confidence intervals (CI). Results: During 521,221 person-years of follow-up, we documented 5,158 cancer cases. Resistance training was not associated with total cancer risk (HR per 1-h/week increase: 1.01; 95% CI 0.97, 1.05). We found an inverse association between resistance training and bladder cancer (HR per 1-h/week increase: 0.80; 95% CI 0.66, 0.96) and kidney cancer (HR per 1-h/week increase 0.77; 95% CI 0.58, 1.03; Ptrend = 0.06), but the association was marginal for the latter after adjustment for confounders and total physical activity. Compared to participants engaging in aerobic activities only, combined resistance training and aerobic activities showed stronger inverse associations with kidney cancer risk. Conclusions: Resistance training was associated with lower risk of bladder and kidney cancers. Future studies are warranted to confirm our findings.
Original language | English |
---|---|
Pages (from-to) | 666-672 |
Number of pages | 7 |
Journal | British journal of cancer |
Volume | 123 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2020 Aug 18 |
Bibliographical note
Funding Information:Funding information This work was supported by the National Institutes of Health (U01 CA167552 and R01 HL35464). L.F.M.R. receives a post-doctoral fellowship from Sao Paulo Research Foundation (FAPESP), grant 2018/23941–9. N.K. was supported by grants from the National Research Foundation of Korea (NRF-2018R1C1B6008822; NRF-2018R1A4A1022589).
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Cancer Research UK.
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research